دورية أكاديمية
Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
| العنوان: | Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. |
|---|---|
| المؤلفون: | Gans HA; Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94305-5208, USA. hagans@stanford.edu, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, Audet S, Maldonado Y, Arvin AM |
| المصدر: | The Journal of infectious diseases [J Infect Dis] 2004 Jul 01; Vol. 190 (1), pp. 83-90. Date of Electronic Publication: 2004 May 26. |
| نوع المنشور: | Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0022-1899 (Print) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press |
| مواضيع طبية MeSH: | Antibodies, Viral/*blood , Measles/*prevention & control , Measles Vaccine/*administration & dosage , Measles virus/*immunology , Measles-Mumps-Rubella Vaccine/*administration & dosage , T-Lymphocytes/*immunology, Humans ; Immunization Schedule ; Infant ; Lymphocyte Activation ; Measles/immunology ; Measles Vaccine/immunology ; Measles-Mumps-Rubella Vaccine/immunology ; Treatment Outcome ; Vaccination |
| مستخلص: | Background: Shifts in peak measles incidence to children <12 months old and the associated high mortality support the study of an early 2-dose measles vaccine regimen. Methods: Fifty-five infants were vaccinated with measles vaccine at age 6 (n=32) or 9 (n=23) months, followed by measles-mumps-rubella (MMR)-II vaccine at age 12 months. A control group received MMR-II only at age 12 months. Measles-specific humoral and cell-mediated immunity were evaluated before, 12 weeks after measles immunization, and 24 weeks after MMR-II. Results: Measles-specific T cell proliferation after both doses of vaccine was equivalent, regardless of age or the presence of passive antibodies. Seroconversion rates, geometric mean titers, and the percentage of infants with antibody titers >120 mIU after the first measles vaccine were lower in infants vaccinated at age 6 months, regardless of the presence of passive antibodies, but measles humoral responses increased after the administration of MMR-II vaccine in children initially vaccinated at age 6 or 9 months. Conclusion: Measles vaccination elicits T cell responses in infants as young as 6 months old, which may prime the humoral response to the second dose. Initiating measles vaccination as an early 2-dose regimen results in an immunologic response that is likely to have clinical benefits in developed and developing countries. |
| معلومات مُعتمدة: | A137127 United States PHS HHS; HD01310 United States HD NICHD NIH HHS; HD33698 United States HD NICHD NIH HHS |
| المشرفين على المادة: | 0 (Antibodies, Viral) 0 (Measles Vaccine) 0 (Measles-Mumps-Rubella Vaccine) |
| تواريخ الأحداث: | Date Created: 20040615 Date Completed: 20040803 Latest Revision: 20071114 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1086/421032 |
| PMID: | 15195246 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0022-1899 |
|---|---|
| DOI: | 10.1086/421032 |